27th Apr 2017 17:40
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Philip Hampton | ||||
b) | Position/status | Non-Executive Chairman | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-04-26 | ||||
f) | Place of the transaction
| n/a | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Professor Sir Roy Anderson | ||||
b) | Position/status | Independent Non-Executive Director | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-04-26 | ||||
f) | Place of the transaction
| n/a | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr Vindi Banga | ||||
b) | Position/status | Senior Independent Non-Executive Director | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information A ggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-04-26 | ||||
f) | Place of the transaction
| n/a | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Dr Vivienne Cox | ||||
b) | Position/status | Independent Non-Executive Director | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-04-26 | ||||
f) | Place of the transaction
| n/a | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Ms Lynn Elsenhans | ||||
b) | Position/status | Independent Non-Executive Director | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | ||||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information A ggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-04-26 | ||||
f) | Place of the transaction
| n/a | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Dr Jesse Goodman | ||||
b) | Position/status | Independent Non-Executive Director | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | ||||
b) | Nature of the transaction | Dr Jesse Goodman was appointed to the Board with effect from 1 January 2016, as previously announced, and in accordance with the share allocation arrangements for Independent Non-Executive Directors, 25% of his fees were retained to be reinvested in notional ADSs at a date to be mutually agreed. The accumulated balance of the retained fees has now been reinvested as disclosed below. Going forward, notional ADSs of the Company will be allocated on a quarterly basis. Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2017.
| ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-04-26 | ||||
f) | Place of the transaction
| n/a | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Ms Judy Lewent | ||||
b) | Position/status | Independent Non-Executive Director | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | ||||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-04-26 | ||||
f) | Place of the transaction
| n/a | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr Urs Rohner | ||||
b) | Position/status | Independent Non-Executive Director | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | ||||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2017-04-26 | ||||
f) | Place of the transaction
| n/a | ||||
Related Shares:
Glaxosmithkline